Sujay Singh Email & Phone Number

San Diego, Ca 92121

Sujan Biologics' goal is to develop biologic drugs against diseases caused by inflammation, such as, arthritis, psoriasis, and certain cancers. In collaboration with IMGENEX India Pvt. Ltd., Sujan Biologics is developing several biosimilar antibodies, such as, Trastuzumab (herceptin), Adalimumab (humira), Bevacizuma (avastin), Ustekinumab (stellara), and Nivolumab (opdivo).Sujan Biologics is also developing some novel bispecific antibodies for the treatment of psoriasis.

Bhubaneswar, Odisha, India

IMGENEX INDIA Pvt. Ltd., is one of the foremost biotechnology company in the Eastern region of India and was founded by Dr. Sujay Singh, Ph.D., in the year 2004 at Bhubaneswar. IMGENEX India has built a state-of-the-art R&D facility at the Infocity complex. The R&D unit of IMGENEX India was inaugurated in 2005 by Dr. APJ Abdul Kalam, the then Hon’ble President of India and is recognized by the Department of Science and Industrial Research (DSIR), Ministry of Science & Technology, Govt. of India. The R&D Unit of IMGENEX India possesses all the modern equipment for molecular biology, recombinant protein production, cell culture, antibody development and other downstream processes. The main goal of IMGENEX India is to provide affordable healthcare to less privileged patients. Over the years IMGENEX India has received several grants from the Department of Biotechnology (DBT) that includes SIBRI grant from to develop drugs for osteoporosis using nanotechnology based drug delivery. It is in the early development phase. In addition to this with grants from BIRAC we have developed a high-yield mammalian expression system in CHO cells that is capable of producing 3-4 g per liter biosimilar Trastuzumab/Herceptin. We hoped to start clinical trial for biosimilar heceptin in the year 2019. Other biosimilars in the pipeline includes Adalimumab (humira), Bevacizuma (avastin), Ustekinumab (stellara), and Nivolumab (opdivo).

San Diego, Ca

Founded IMGENEX Corporation in 1997 to develop high quality research tools including monoclonal antibodies, ELISA kits, siRNAs, and tissue microarrays for biomedical research. IMGENEX was sold to Novus Biologicals in 2013.

San Diego, Ca

Supervising a group of scientists for development and characterization of monoclonal antibodies against proteins involved in signal transduction, apoptosis, neurotransmission, and infectious diseases, etc. Working with the marketing group, helped commercialization of these antibodies and other reagents for biomedical research.